Latest Information Update: 26 May 2011
At a glance
- Originator Bayer
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Brain injuries; Stroke
Most Recent Events
- 18 Aug 2008 No development reported - Preclinical for Stroke in Germany (unspecified route)
- 18 Aug 2008 No development reported - Preclinical for Brain injuries in Germany (unspecified route)
- 22 Sep 2000 Preclinical development for Brain injuries in Germany (Unknown route)